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Abstract
Objective To determine the relationship between interventricular septal position (SP) and right ventricular systolic pressure
(RVSP) and mortality in infants with severe BPD (sBPD).
Study design Infants with sBPD in the Children’s Hospitals Neonatal Database who had echocardiograms 34–44 weeks’
postmenstrual age (PMA) were included. SP and RVSP were categorized normal, abnormal (flattened/bowed SP or RVSP >
40 mmHg) or missing.
Results Of 1157 infants, 115 infants (10%) died. Abnormal SP or RVSP increased mortality (SP 19% vs. 8% normal/
missing, RVSP 20% vs. 9% normal/missing, both p < 0.01) in unadjusted and multivariable models, adjusted for significant
covariates (SP OR 1.9, 95% CI 1.2–3.0; RVSP OR 2.2, 95% CI 1.1–4.7). Abnormal parameters had high specificity
(SP 82%; RVSP 94%), and negative predictive value (SP 94%, NPV 91%) for mortality.
Conclusions Abnormal SP or RVSP is independently associated with mortality in sBPD infants. Negative predictive values
distinguish infants most likely to survive.
Introduction
Severe bronchopulmonary dysplasia (sBPD) affects
approximately 20% of extremely low-birthweight infants
[1]. Pulmonary arterial hypertension (PH) can occur in
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15–25% of infants with sBPD, and is associated with an
increased risk of mortality [2–4]. Recognizing this concern,
the American Heart Association recommends screening
echocardiography to monitor for PH in infants with BPD
[5]. However, echocardiographic parameters are limited by
subjective, varied, or missing measures, as well as modest
correlation with pulmonary arterial pressure measured via
cardiac catheterization [6–9]. Further, screening for PH
often varies from center to center. Understanding whether
standard clinically used echocardiographic parameters of
PH are associated with mortality would help to inform
clinical practices with respect to screening infants with
sBPD for PH.
Our objective was to determine whether interventricular
septal position and right ventricular systolic pressure on
echocardiography performed between 34 and 44 weeks’
post-menstrual age (PMA) were associated with in-hospital
mortality in infants with sBPD. We hypothesized that these
measures could be used to predict inpatient mortality in a
real-world clinical cohort.
Methods
We performed a secondary analysis of data from the Chil-
dren’s Hospitals Neonatal Database (CHND), which
includes prospectively collected data on all infants admitted
to participating Level IV neonatal intensive care units
(NICUs) in the United States and Canada. Infant clinical
data were collected by trained chart abstractors at each site,
with periodic assessments of inter-rater agreement scores
[10]. De-identified data analyses were approved by the
Institutional Review Board of Stanley Manne Research
Institute affiliated with the Ann and Robert H. Lurie Chil-
dren’s Hospital of Chicago. All participating centers
obtained regulatory oversight to participate in the CHND
registry.
We included infants born <32 weeks’ gestation who
were admitted to a participating NICU between 2010 and
2015, who had sBPD, and who had at least one echo-
cardiogram between 34 and 44 weeks’ PMA. sBPD was
defined as receiving positive pressure ventilation, >2 L/min
flow by nasal cannula, or fractional inspired oxygen (FiO2)
> 0.3 at or after 36 weeks’ PMA [2, 10, 11]. Infants were
excluded if they died prior to 36 weeks’ PMA, were
transferred out of the participating hospital before dis-
charge, or if they had major congenital anomalies. Infants
with an isolated atrial septal defect, ventricular septal defect,
or patent ductus arteriosus were retained in the study.
The primary outcome was mortality between 36 weeks’
PMA and discharge from a CHND hospital. Primary
exposures of interest were echocardiographic measures of
interventricular septal position (SP) and right ventricular
systolic pressure (RVSP) recorded between 34 and
44 weeks’ PMA. SP was defined as abnormal if there was
documentation of septal position being flattened or bowed
to the left. RVSP was categorized as abnormal if the result
was >40 mmHg; this cut-off was determined a priori cor-
responding to values >40 mmHg being more than half of the
systemic blood pressure [7, 12, 13]. For infants with mul-
tiple echocardiograms, we examined all reports occurring
between 34 and 44 weeks PMA; we categorized the infant
as having an abnormal echocardiographic parameter if any
available studies had an abnormal parameter. If no available
echocardiography reports documented RVSP or SP, we
categorized the data as missing and retained that infant in
the dataset. Direction of flow across the patent ductus
arteriosus (PDA) and the interatrial septum were not con-
sidered as exposures for this study because the PDA was
closed and interatrial septal flow was minimal in nearly all
subjects between 34 and 44 weeks’ PMA. Instead, PDA
ligation and interatrial communication were included as
potential covariates.
We included other clinical covariates available in the
CHND that we hypothesized might confound the relation-
ship between echocardiographic parameters and mortality.
Maternal characteristics included were race, diabetes,
hypertension, chorioamnionitis, multiple gestation, and
receipt of antenatal steroids. Neonatal characteristics
included gestational age, birthweight, small for gestational
age (defined as sex-specific ≤ 10th percentile of birthweight
for gestational age) [14], duration of mechanical ventilation
in the CHND nursery, receipt of mechanical ventilation at
36 weeks’ PMA, receipt of systemic corticosteroids,
bloodstream infections, atrial septal communications, or
PDA ligation. A respiratory severity score was also calcu-
lated as a product of the mean airway pressure and the
fractional oxygen requirement (MAP × FiO2) at 36 weeks’
PMA and compared between groups (see Table 1). Blood-
stream infections were defined as any confirmed bacterial or
fungal organisms recovered from a blood culture during the
hospital admission. Necrotizing enterocolitis was defined as
any of the following conditions: (1) Surgical NEC; (2) NEC
at post-mortem examination or (3) if both clinical symptoms
(bilious aspirate or emesis, abdominal distention, and
occult/gross blood in stool) and radiographic findings
(pneumotosis intestinalis, hepatobiliary gas or pneumoper-
itonem) were present. These findings correspond to a NEC
Stage IIb or higher. Airway comorbidities were defined as
laryngeal, tracheal, or bronchial malacia, laryngeal or tra-
cheal stenosis, or vocal cord paralysis or paresis.
Statistical analysis
We first assessed the proportion of echocardiographic
parameters that were normal, abnormal and missing in the
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Table 1 Baseline cohort demographics by septal position and right ventricular systolic pressure
Septal position variables Septum abnormal Septum data
missing
Septum normal p value
N (%) 227 (20) 314 (27) 616 (53)
Gestational age (weeks) median (IQR) 25 (24, 26) 25 (24, 27) 25 (24, 27) 0.002
Admission PMA (weeks) median (IQR) 29 (26, 36) 28 (26, 31) 29 (26, 33) 0.003
PMA at echocardiogram (wks)
median (IQR)
31 (27, 40) 30 (27, 36) 31 (27, 37) 0.017
Birthweight (g) median (IQR) 680 (580, 790) 740 (610, 910) 766 (640, 940) 0.000
≤10th centile, n (%) 59 (26) 55 (18) 112 (18) 0.023
Maternal race, n (%) 0.031
White 105 (46) 171 (55) 325 (53)
Black 95 (42) 93 (30) 216 (35)
Other 24 (11) 39 (12) 67 (11)
Unknown 3 (1) 11 (4) 8 (1)
Ventilator days median (IQR) 55 (28, 92) 46.5 (19, 83) 42 (20, 71) 0.002
Ventilator at 36 weeks’ PMA, n (%) 120 (53) 127 (41) 233 (38) 0.000
MAP × FiO2 @ 36 weeks’ PMA for
ventilated patients median (IQR)
4 (3, 7) 2 (0, 5) 3 (2, 6) 0.000
Systemic steroids, n (%) 113 (50) 91 (29) 276 (45) 0.000
Fundoplication, n (%) 37 (16) 20 (6) 61 (10) 0.001
Bloodstream infection, n (%) 69 (30) 92 (29) 141 (23) 0.028
Atrial septal defect, n (%) 62 (28) 28 (9) 62 (10) 0.000
PMA at PDA Ligation median (IQR) 32 (29, 39) 30 (28, 33) 30 (28, 32) 0.001
RVSP variables RVSP >40mmHg RVSP missing RVSP ≤40 mmHg p value
N (%) 84 (7) 843 (73) 230 (20)
Gestational age (weeks) median (IQR) 25 (24, 26) 25 (24, 27) 25 (24, 26) 0.000
PMA at echocardiogram (wks)
median (IQR)
34 (27, 40) 30 (27, 37) 30 (26, 37) 0.020
Birthweight (g) median (IQR) 668 (570, 826) 760 (630, 941) 703 (585, 812) 0.000
Male gender, n (%) 39 (46) 530 (63) 133 (58) 0.008
Maternal race, n (%)
White 38 (45) 460 (55) 103 (45) 0.009
Black 35 (42) 280 (33) 89 (39)
Other 10 (12) 83 (10) 37 (16)
Unknown 1 (1) 20 (2) 1 (0)
Multiple births, n (%) 12 (14) 210 (25) 52 (23) 0.017
Atrial septal defect, n (%) 16 (19) 99 (12) 39 (17) 0.033
PMA at PDA ligation median (IQR) 37 (30, 39) 30 (28, 33) 29 (28, 31) 0.000
Baseline cohort demographics by septal flattening and right ventricular systolic pressure measurements
Baseline demographic and clinical variables were compared between septal flattening categories of abnormal position (flattened or bowed), septal
position data missing, and normal position; and right ventricular systolic pressure (RVSP) categories of RVSP abnormal (>40 mmHg), RVSP data
missing, or RVSP normal (≤40 mmHg). Chi-square tests were used to compare proportions and t tests or nonparametric tests were used to compare
medians of continuous variables
Septal position did not differ between groups with respect to male gender, maternal chorioamnionitis, maternal diabetes, maternal hypertension,
multiple births, antenatal steroids, airway comorbidity, tracheostomy, gastrostomy, surgical necrotizing enterocolitis, ventricular septal defect, and
PDA ligation (p > 0.05). Median admission PMA and ventilator days did not differ between RVSP groups. The proportion of infants with
birthweight <10th%, with maternal chorioamnionitis, diabetes, or hypertension, receiving antenatal steroids, on the ventilator at 36 weeks’ PMA,
with airway comorbidities, with tracheostomy, with surgical necrotizing enterocolitis, with gastrostomy or fundoplication, with bloodstream
infections, with ventricular septal defects, or with PDA ligations did not differ between RVSP groups (p ≥ 0.05)
PMA post-menstrual age, MAP mean airway pressure, PDA patent ductus arteriosus
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study cohort. We compared the clinical characteristics by
SP and RVSP groups of normal, abnormal and missing,
using chi-squared or Fisher’s exact tests for differences in
proportion and Kruskal−Wallis nonparametric tests for
differences of medians. For the unadjusted association
between echocardiographic parameters and mortality, we
calculated the sensitivity, specificity, positive and negative
predictive value, and relative risk. Next, all covariates with
bivariate association of p < 0.05 were entered into multi-
level multivariable logistic regression models with center as
a random intercept. Because we assumed the echocardio-
graphic exposure variables to be collinear, we ran two
separate models, one with septal position alone as the
exposure, and one with RVSP alone as the exposure. For
each model, abnormal and missing echocardiographic
parameters were each tested against a referent group of
infants with normal echocardiographic parameters. Statis-
tical significance was defined as p value < 0.05. SAS v 9.2
(SAS Institute, Cary, North Carolina) was used for analyses.
Results
The database included 12,221 infants born <32 weeks’
gestation who were alive at 36 weeks’ PMA and who did
not have congenital anomalies. Of those, 2806 infants had
sBPD and 1412 (50%) infants with sBPD had one or more
echocardiograms between 34 and 44 weeks’ PMA. We
excluded 255 infants who were transferred to another hos-
pital before discharge. This resulted in a study cohort of
1157 infants; 1042 (90%) survived to hospital discharge,
while 115 (10%) died. Infants who died had a later PMA at
admission to the NICU (median 31 days [IQR 27–38] vs. 28
[IQR 26–33], p < 0.001), lower birthweight (median 685 g
[IQR 560–840] vs. 748 g [IQR 620–910], p= 0.001), were
on the ventilator longer (median 102 days [IQR 51–144] vs.
42 days [IQR 19–71], p < 0.001), and were more likely to
have received systemic corticosteroids (69% vs. 38%, p <
0.001) or to have received a diagnosis of necrotizing
enterocolitis (22% vs. 10%, p= 0.001) than infants who
survived. The cause of death in our cohort was primarily
respiratory failure (67%, n= 77/115), followed by multi-
organ system failure (16%, n= 18/115). Forty-six infants
(60%, n= 46/77) who died of respiratory causes also had a
clinical diagnosis of pulmonary hypertension. Less common
causes of death were intra-abdominal catastrophe (4%),
central nervous system injury (3%), infection (3%), renal
failure (3%), and other causes (4%). Infants with abnormal
septal position and RVSP had a median of 2 echocardio-
grams, and infants with normal or missing parameters had a
median of one echocardiogram during their neonatal hos-
pitalization. As shown in Table 1, infants with abnormal
RVSP measurements had echocardiograms performed at a
slightly later PMA those with normal measurements
(34 weeks vs. 30 weeks), and the median PMA of echo-
cardiogram attainment in infants with abnormal and normal
septal position was 31 weeks.
Septal position (SP) was categorized as normal in 616
(53%) infants, abnormal in 227 (20%) infants, and missing
in 314 (27%) of infants. Table 1 (top) compares char-
acteristics of infants by SP. SP groups differed with respect
to gestational age and birthweight, age at referral to CHND
NICU, birthweight < 10th percentile for gestational age,
maternal race, duration of mechanical ventilation, respira-
tory severity score at 36 weeks’ PMA, receipt of systemic
corticosteroids, bloodstream infections, and atrial septal
defects. The proportion of infants receiving PDA ligation
was similar between groups but the PMA at PDA ligation
was later in infants with abnormal SP. Infants with missing
SP had clinical characteristics that were similar to those of
infants with normal position. RVSP was categorized as
normal in 230 (20%) infants, abnormal in 84 (7%), and
missing in 843 (73%). Table 1 (bottom) compares char-
acteristics of infants by RVSP. RVSP categories differed in
categories of birthweight, sex, maternal race, singleton birth
and atrial septal defects. Rates of PDA ligation were similar
between groups but the median PMA at ligation was later in
infants with abnormal RVSP. Infants with missing RVSP
had the largest birthweight, the lowest receipt of postnatal
systemic steroids, and the lowest proportion of atrial septal
defects.
Abnormal SP and RVSP were each associated with
higher odds of mortality (Table 2, top). In unadjusted ana-
lysis, abnormal SP was associated with 2.6-fold increase in
mortality, and after adjustment for significant covariates, SP
was associated with 1.9-times the odds of mortality, when
compared with infants with normal SP (p= 0.01). However,
infants with missing SP did not have significantly different
odds of mortality from those with normal SP. Receiving
ventilation at 36 weeks’ PMA, having a bloodstream
infection, receiving postnatal steroids, and being admitted at
a later PMA were also significant risk factors for mortality
in both unadjusted and adjusted SP models. Similarly, in
both unadjusted models and adjusted models, abnormal
RVSP was associated with a 2.2-fold increase in mortality
(p= 0.02), whereas infants with missing RVSP data had
mortality rates that were similar to infants with normal
RVSP values (Table 2, bottom). Ventilation at 36 wks’
PMA, bloodstream infection, postnatal steroid use, and
admission PMA remained significantly associated with
mortality in adjusted RVSP models. Whereas atrial septal
defects marginally increased the odds of mortality in SP
models, the presence of an interatrial communication sig-
nificantly increased mortality by 1.9-fold in RVSP models.
Overall, infants with abnormal septal position had a
mortality rate that was 19% compared with 8% of infants
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with normal SP, and 8% for infants with normal/missing
data (abnormal SP n= 43/227 vs. normal SP n= 50/616 or
normal/missing SP n= 72/930). Mortality for infants with
abnormal RVSP was 20% (n= 17/84) compared with 10%
for infants with normal data (n= 24/230) and 9% for infant
with normal/missing data (n= 98/1073).
Test characteristics of the abnormal echocardiographic
parameters are shown in Table 3. When comparing infants
with abnormal SP or RVSP to those with normal para-
meters, these parameters were highly specific (82% and
94%, respectively) but poorly sensitive (37% and 15%)
markers of mortality. The negative predictive value was
over 90% for each parameter. This pattern was nearly
identical when comparing abnormal SP or RVSP to infants
either a normal or missing parameter.
Discussion
In this multicenter clinical cohort of infants with sBPD, we
found that septal position and RVSP > 40 mmHg were
significantly associated with in-hospital mortality after
adjusting for significant clinical characteristics. We also
found that infants with missing documentation of RVSP
and/or septal position had clinical and mortality outcomes
similar to those with documented normal echocardiographic
parameters.
Pulmonary hypertension is a significant contributor to
morbidity and mortality in premature infants with BPD
[2, 15–18]. In 2015, the American Heart Association
recommended echocardiographic screening of infants with
Table 3 Sensitivity analyses for mortality by echocardiographic
parameter
Echocardiographic variable Sensitivity Specificity PPV NPV
Septal position
Abnormal vs. normal 46% 75% 19% 92%
Abnormal vs. normal/missing 37% 82% 19% 92%
RVSP > 40 mmHg
Abnormal vs. normal 41% 75% 20% 90%
Abnormal vs. normal/missing 15% 94% 20% 91%
Mortality rates for infants with abnormal SP were 19% compared with
8% for infants with normal or normal/missing data. Mortality rates for
infants with abnormal RVSP were 20% compared with 9–10% for
infants with normal or normal/missing data. Test characteristics of
sensitivity, specificity, positive-predictive value (PPV) and negative
predictive value (NPV) are shown









Abnormal vs. Normal* 2.6 1.7–4.1 1.9 1.2–3.0
Missing vs. Normal 0.9 0.5–1.4 0.9 0.5–1.5
Gestational age 1.0 0.9–1.1 1.0 0.9–1.1
Ventilated at 36 weeks’ PMA* 6.7 4.2–10.8 5.3 3.2–8.6
Atrial septal defect 1.7 1.1–2.8 1.6 1.0–2.8
Bloodstream infection* 1.7 1.1–2.5 1.8 1.1–2.8
Postnatal steroids* 3.9 1.9–8.1 2.4 1.1–5.2
PMA at admission* (per postnatal week) 1.1 1.0–1.1 1.1 1.0–1.1
RVSP
Abnormal vs. normal* 2.2 1.1–4.3 2.2 1.1–4.7
Missing vs. normal 0.8 0.5–1.3 0.9 0.6–1.6
Gestational age 1.0 0.9–1.1 1.0 0.9–1.1
Ventilated at 36 weeks’ PMA* 6.7 4.2–10.8 5.7 3.5–9.4
Atrial septal defect* 1.7 1.1–2.8 1.9 1.1–3.2
Bloodstream infection* 1.7 1.1–2.5 1.7 1.1–2.8
Postnatal steroids* 3.9 1.9–8.1 2.4 1.1–5.2
PMA at admission* (per postnatal week) 1.1 1.0–1.1 1.1 1.0–1.1
Multivariable models were constructed to evaluate the effect of septal position alone, and right ventricular
systolic pressure (RVSP) alone on mortality. Significant clinical covariates, including gestational age, the
need for ventilation at 36 weeks’ postmenstrual age, the presence of an atrial septal defect, the diagnosis of a
bloodstream infection, the receipt of postnatal steroids and the postmenstrual age in weeks at the time of
admission, were controlled in each model. Odds ratios and 95% confidence intervals were calculated using
logistic regression
*p < 0.05 in multivariable models
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moderate or severe BPD beginning at 36 weeks PMA with
serial echocardiography thereafter [5]. Compared to cardiac
catheterization, echocardiographic screening for PH has
been limited in its ability to detect and grade the severity of
pulmonary hypertension [7]. We found that infants with
documented abnormal RVSP or septal position had
approximately double the odds of mortality, compared to
infants with normal echocardiographic parameters. This
association persisted even after adjusting for other sig-
nificant predictors of mortality including gestational age,
receipt of mechanical ventilation at 36 weeks’ PMA, atrial
septal defect, bloodstream infection, postnatal corticosteroid
use, and PMA at admission to the participating center.
These results demonstrate that even among sick neonates
with severe BPD, abnormal SP and RVSP are independent
predictors of mortality. In that context, our results demon-
strating the potential impact of real-world echocardio-
graphic data provide further support for adherence to the
new guidelines.
When we compared infants with missing echocardio-
graphic data to infants with normal parameters for septal
position, we found that infants with missing data had an
odds of mortality that was similar to infants with normal
echocardiographic parameters. Mourani et al. found that
the sensitivity and positive-predictive value of echo-
cardiographic parameters for the detection of PH is
enhanced when tricuspid regurgitant jet velocity can be
measured as a proxy for pulmonary artery pressure [7].
Unfortunately, several studies have noted the challenge of
obtaining tricuspid regurgitant jet velocity measurements,
even when echocardiography is being performed in
accordance with prespecified research protocols and on
older pediatric patients [19, 20]. Indeed, in our cohort,
tricuspid regurgitant jet velocity and resultant right ven-
tricular systolic pressure was recorded in only 27% of
echocardiographic reports, highlighting the practical lim-
itations of obtaining this important variable at the bedside.
Septal position was more commonly documented in our
cohort, with 73% of echocardiographic reports having
documentation of septal position. Assignment of septal
position may be subject to considerable subjectivity and
interobserver variability [21]. More quantitative measures
of septal position, such as eccentricity index, are now
being investigated in infants with BPD and hold promise
as a means of standardizing the echocardiographic
approach [19, 22]. Nonetheless, our finding that infants
with missing echocardiographic data had mortality rates
similar to infants with documented normal echocardio-
graphic parameters suggests that the inherent difficulties
of obtaining standard echocardiographic measurements
should not prevent efforts at screening. Further, echo-
cardiography correctly identified infants who were likely
to survive, as shown by the high specificity and negative
predictive values of both septal flattening and RVSP in
our study. As such, septal position and RVSP measures on
echocardiography between 34 and 44 weeks’ PMA can be
helpful in delineating risk status for in-hospital mortality
in infants with sBPD.
Surprisingly, only half of our initial cohort of infants
with severe BPD had screening echocardiography between
34 and 44 weeks’ PMA. This finding is in keeping with
recent surveys of neonatal members of the American
Academy of Pediatrics. This survey found that 83% of
physicians would obtain an echocardiogram at 36 weeks’
corrected gestational age for infants with moderate or severe
BPD, but only 46% of respondents had a formal screening
program in place at their institution that facilitated the
implementation of these guidelines [23]. Our study cohort
occurred prior to the publication of the recent American
Heart Association screening guidelines; future work,
including our observations in this study, should serve to
increase the rate of screening for PH in infants with BPD.
Quality initiatives to standardize the approach to PH
screening in infants with BPD across sites are now being
developed. Even as screening efforts advance, we
acknowledge that data are limited on whether early detec-
tion and pharmacologic treatment of pulmonary hyperten-
sion in infants with severe BPD improves survival.
Retrospective evaluations of this association may be pla-
gued with concerns about confounding by indication, and
the feasibility and cost of randomized controlled trials can
be prohibitive. Additionally, the natural course of milder
forms of pulmonary hypertension is to resolve without
pharmacologic therapy [24, 25]. However, identifying the
patients at risk for poor outcomes is essential in the neonatal
period to allow appropriate risk categorization and follow-
up after hospital discharge. Overall, one in four infants with
severe BPD may develop pulmonary hypertension, but 41
−62% will be diagnosed after hospital discharge and will
experience morbidity and mortality in the first year of life as
a result of their diagnosis [1, 2, 24, 26]. As such, even while
the efficacy of pharmacologic therapy for pulmonary
hypertension is being evaluated, echocardiographic screen-
ing for infants with severe BPD may allow proven inter-
ventions such as aggressive management of respiratory
acidosis, prevention of intermittent hypoxia, targeting of
optimal nutrition and feeding modes, and engagement of
multidisciplinary care to be employed early and aggres-
sively in order to improve outcomes for high-risk infants
[1, 27–31].
Our study has important limitations. Our cohort was
derived from a referral-based, quaternary care population
and may not be generalizable to other cohorts. We further
recognize that the infants in our cohort had severe BPD, and
although controlling for the need for mechanical ventilation
at 36 weeks’ post-menstrual age may have adjusted for the
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sickest patients, it is possible that associations between
echocardiographic parameters and mortality may differ in
infants with less severe lung disease. The echocardiograms
in our study were performed at clinical discretion, which
may lead to some ascertainment and selection bias in our
sample.
In conclusion, we have shown that abnormalities in
echocardiographic parameters, such as septal flattening and
RVSP, are associated with nearly a two-fold increase in the
odds of mortality prior to hospital discharge in infants with
severe BPD. This association persists after controlling for
important clinical variables. Further, infants with normal
parameters are more likely to survive their initial hospita-
lization than those with abnormal values in our cohort.
These findings support the recommendation to implement
pulmonary hypertension screening for infants with severe
BPD despite the known limitations of echocardiography in
a neonatal population. Future quality improvement initia-
tives that define the timing and standardize the optimal
approach to echocardiography in this high-risk population
are warranted.
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